Latest News - Bristol-Myers Squibb

Thursday, January 03, 2019

Bristol-Myers Squibb to Acquire Celgene

Bristol-Myers Squibb Company will acquire Celgene Corp. in a cash and stock transaction with an equity value of approximately $74 billion. The combined company with complementary areas of focus, will …

Read the full story

Monday, October 22, 2018

Opdivo Plus Yervoy Demonstrates Durable Four-Year Survival Benefits in Advanced Melanoma

Four-year data from the Phase 3 CheckMate-067 clinical trial -- the longest follow-up to date -- continue to demonstrate durable, long-term survival benefits with the first-line combination of Op…

Read the full story

Friday, July 20, 2018

Game On: Head-to-head Trials to Enhance Competition in PsO Market

An increase in head-to-head trials will enhance the competition within the psoriasis market, according to GlobalData. The first major biologics that were released were anti-tumor necrosis factor (a…

Read the full story

Friday, June 08, 2018

Opdivo Data: Superior Recurrence-Free Survival Versus Ipilimumab

Updated results from the Phase 3 CheckMate -238 trial evaluating Opdivo (nivolumab, Bristol-Myers Squibb Company) versus Yervoy (ipilimumab, Bristol-Myers Squibb Company) …

Read the full story

Thursday, January 04, 2018

FDA Approves BMS's Opdivo as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Disease

The FDA has approved Bristol-Myers Squibb Company's Opdivo (nivolumab) injection for intravenous use for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metasta…

Read the full story

Monday, July 24, 2017

FDA Expands Approval of Yervoy to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma

The FDA has expanded the indication for Bristol-Myers Squibb's Yervoy (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatr…

Read the full story